Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Cash from Financing Activities data on record, last reported at $118.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 105857.14% year-over-year to $118.7 million; the TTM value through Dec 2025 reached $126.4 million, up 178.8%, while the annual FY2025 figure was $126.4 million, 178.8% up from the prior year.
  • Cash from Financing Activities reached $118.7 million in Q4 2025 per CCCC's latest filing, up from $7.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $170.5 million in Q2 2021 and bottomed at -$10.8 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $20.5 million, with a median of $361000.0 recorded in 2022.
  • The widest YoY moves for Cash from Financing Activities: up 122606.38% in 2023, down 3078.67% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $466000.0 in 2021, then tumbled by 89.91% to $47000.0 in 2022, then soared by 122606.38% to $57.7 million in 2023, then tumbled by 99.81% to $112000.0 in 2024, then surged by 105857.14% to $118.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $118.7 million in Q4 2025, $7.8 million in Q3 2025, and -$46000.0 in Q1 2025.